Susquehanna International Group’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.08M | Sell |
140,400
-161,800
| -54% | -$2.36M | ﹤0.01% | 6100 |
|
|
2025
Q4 | $4.82M | Sell |
302,200
-107,200
| -26% | -$1.52M | ﹤0.01% | 4083 |
|
|
2025
Q3 | $4.52M | Buy |
409,400
+4,400
| +1% | +$48.1K | ﹤0.01% | 4243 |
|
|
2025
Q2 | $3.43M | Sell |
405,000
-73,400
| -15% | -$588K | ﹤0.01% | 4702 |
|
|
2025
Q1 | $3.85M | Buy |
478,400
+348,100
| +267% | +$2.82M | ﹤0.01% | 4155 |
|
|
2024
Q4 | $1.17M | Sell |
130,300
-334,300
| -72% | -$2.73M | ﹤0.01% | 6572 |
|
|
2024
Q3 | $3.41M | Buy |
464,600
+313,100
| +207% | +$1.94M | ﹤0.01% | 4319 |
|
|
2024
Q2 | $865K | Sell |
151,500
-159,800
| -51% | -$842K | ﹤0.01% | 6925 |
|
|
2024
Q1 | $1.56M | Buy |
311,300
+195,600
| +169% | +$1.33M | ﹤0.01% | 5913 |
|
|
2023
Q4 | $1.04M | Sell |
115,700
-108,200
| -48% | -$891K | ﹤0.01% | 6905 |
|
|
2023
Q3 | $1.74M | Buy |
223,900
+32,700
| +17% | +$320K | ﹤0.01% | 5420 |
|
|
2023
Q2 | $1.85M | Sell |
191,200
-5,900
| -3% | -$61.2K | ﹤0.01% | 5310 |
|
|
2023
Q1 | $2.16M | Sell |
197,100
-93,300
| -32% | -$822K | ﹤0.01% | 4968 |
|
|
2022
Q4 | $1.25M | Sell |
290,400
-306,200
| -51% | -$1.78M | ﹤0.01% | 5693 |
|
|
2022
Q3 | $4.49M | Buy |
596,600
+81,000
| +16% | +$701K | ﹤0.01% | 3346 |
|
|
2022
Q2 | $5.18M | Sell |
515,600
-714,000
| -58% | -$7.98M | ﹤0.01% | 3126 |
|
|
2022
Q1 | $15.2M | Sell |
1,229,600
-394,200
| -24% | -$6.09M | ﹤0.01% | 2008 |
|
|
2021
Q4 | $37.1M | Buy |
1,623,800
+807,700
| +99% | +$19.1M | 0.01% | 1313 |
|
|
2021
Q3 | $18.1M | Sell |
816,100
-9,900
| -1% | -$157K | ﹤0.01% | 2082 |
|
|
2021
Q2 | $10.7M | Buy |
826,000
+449,900
| +120% | +$5.73M | ﹤0.01% | 2820 |
|
|
2021
Q1 | $4.88M | Buy |
376,100
+226,700
| +152% | +$3.29M | ﹤0.01% | 3951 |
|
|
2020
Q4 | $2.07M | Sell |
149,400
-165,300
| -53% | -$2.41M | ﹤0.01% | 5027 |
|
|
2020
Q3 | $4.64M | Buy |
314,700
+17,900
| +6% | +$259K | ﹤0.01% | 3151 |
|
|
2020
Q2 | $4.82M | Sell |
296,800
-70,900
| -19% | -$1.14M | ﹤0.01% | 3059 |
|
|
2020
Q1 | $5.33M | Sell |
367,700
-71,400
| -16% | -$1.26M | ﹤0.01% | 2497 |
|
|
2019
Q4 | $8.9M | Buy |
439,100
+5,400
| +1% | +$49.7K | ﹤0.01% | 2211 |
|
|
2019
Q3 | $2.32M | Buy |
433,700
+169,700
| +64% | +$1.03M | ﹤0.01% | 3916 |
|
|
2019
Q2 | $1.74M | Buy |
264,000
+235,700
| +833% | +$1.5M | ﹤0.01% | 4455 |
|
|
2019
Q1 | $184K | Sell |
28,300
-31,800
| -53% | -$211K | ﹤0.01% | 7930 |
|
|
2018
Q4 | $410K | Sell |
60,100
-151,400
| -72% | -$873K | ﹤0.01% | 6395 |
|
|
2018
Q3 | $1.4M | Buy |
211,500
+166,700
| +372% | +$935K | ﹤0.01% | 4601 |
|
|
2018
Q2 | $252K | Buy |
44,800
+3,300
| +8% | +$18.4K | ﹤0.01% | 8173 |
|
|
2018
Q1 | $215K | Sell |
41,500
-4,500
| -10% | -$24.1K | ﹤0.01% | 8206 |
|
|
2017
Q4 | $208K | Sell |
46,000
-92,400
| -67% | -$513K | ﹤0.01% | 8217 |
|
|
2017
Q3 | $868K | Sell |
138,400
-88,200
| -39% | -$556K | ﹤0.01% | 5526 |
|
|
2017
Q2 | $1.39M | Buy |
226,600
+55,000
| +32% | +$371K | ﹤0.01% | 4585 |
|
|
2017
Q1 | $1.26M | Sell |
171,600
-118,700
| -41% | -$548K | ﹤0.01% | 4647 |
|
|
2016
Q4 | $610K | Buy |
+290,300
| New | +$934K | ﹤0.01% | 6567 |
|
Other funds holding AUPH
TCM
NMC
Susquehanna International Group's AUPH Position: Q1 2026 in Review
Susquehanna International Group increased its Aurinia Pharmaceuticals (AUPH) stake by 60% in Q1 2026, buying an estimated $221K and bringing the position to 40,537 shares worth $601K. The position accounts for ﹤0.01% of the portfolio, ranked #9198.
Susquehanna International Group first reported a position in AUPH in Q4 2016 and has held it in 37 quarters since. The position peaked at $84.6M in Q3 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- Susquehanna International Group held 40,537 shares of Aurinia Pharmaceuticals worth $601K as of Q1 2026.
- Susquehanna International Group bought 15,153 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $221K.
- Aurinia Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9198 holding.
- Susquehanna International Group first reported a position in Aurinia Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
- Susquehanna International Group's Aurinia Pharmaceuticals position peaked at $84.6M in Q3 2021.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.